Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-posi...Подробнее

Overall survival (OS) results of the Phase III MONALEESA-3 trialПодробнее

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...Подробнее

GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..."Подробнее

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancerПодробнее

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBCПодробнее

Discussing the Latest Results From the MONALEESA-3 StudyПодробнее

Practical Implications of the MONALEESA-3 TrialПодробнее

MONARCH 2: Overall survival results from abermaciclib plus fulvestrant in HR+ HER2- advanced bre...Подробнее

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancerПодробнее

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 studyПодробнее

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozoleПодробнее

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine ther...Подробнее

PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABCПодробнее

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast CancerПодробнее

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 studyПодробнее

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic br...Подробнее

Potential in the MONALEESA-7 and MONALEESA-3 TrialsПодробнее

Toxicities Associated with Ribociclib From MONALEESA-3 TrialПодробнее